Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome wide DNA methylation study of Parkinson's disease in whole blood samples

ABSTRACT: Genome wide DNA methylation study of Parkinson's disease in whole blood samples

PROVIDER: PRJNA437618 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genome wide DNA methylation study of Parkinson's disease in whole blood samples

Project description:Genome wide DNA methylation profiling of whole blood and saliva samples in Parkinson's disease (PD) patients and PD-free controls. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles. Samples included 335 PD patients and 237 controls with blood DNA.

2018-03-10 | GSE111629 | GEO

Genome-wide DNA methylation study of Parkinson's disease in saliva samples

Project description:Genome wide DNA methylation profiling of saliva samples in Parkinson's disease (PD) patients and PD-free controls. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles. Samples included 128 PD patients and 131 controls with saliva DNA.

2018-03-02 | GSE111223 | GEO

DNA methylation profiles of human blood samples from Caucasian subjects with Parkinson's disease

Project description:Human DNA methylation Beadchip v1.2 was used to profile 508 whole blood samples. The main goal of the study was to relate Parkinson's disease status to measures of epigenetic age acceleration based on DNA methylation data. Here we focus on Caucasian subjects. To measure DNA methylation age, we used the epigenetic clock software described in Horvath S (n=2013) DNA methylation age of human tissues and cell types. Genome Biology.2013, 14:R115. DOI: 10.1186/10.1186/gb-2013-14-10-r115 PMID: 24138928.

2018-09-04 | GSE72774 | GEO

Epigenome analysis of Parkinson's disease and control samples from the Systema Genomics Parkinson's disease (SGPD) consortium

Project description:Genome wide DNA methylation association analysis of Parkinson's disease and control samples. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 450,000 CpGs in blood samples. Samples included 1001 Parkinson's disease cases and 973 controls.

2020-02-17 | GSE145361 | GEO

DNA methylation profiles of human blood samples from Hispanic subjects with Parkinson's disease

Project description:Human DNA methylation Beadchip v1.2 was used to profile n=84 whole blood samples from Hispanics living in the USA. The main goal of the study was to relate Parkinson's disease status to measures of epigenetic age acceleration based on DNA methylation data. Here we focus on Hispanic subjects. To measure DNA methylation age, we used the epigenetic clock software described in Horvath S (n=2013) DNA methylation age of human tissues and cell types. Genome Biology.2013, 14:R115. DOI: 10.1186/10.1186/gb-2013-14-10-r115 PMID: 24138928.

2018-09-04 | GSE72776 | GEO

Genome-wide DNA methylation study of Parkinson's disease in saliva samples

Project description:Genome-wide DNA methylation study of Parkinson's disease in saliva samples

| PRJNA436231 | ENA

Gene Expression in the Blood of Parkinson's Disease Patients

Project description:Peripheral blood was collected from 18 Parkinson's Disease (PD) patients and 12 healthy controls (Ctrls). Total RNA was isolated and hybridized onto Affymetrix Exon_ST1 arrays to find in PDs versus controls: 1) genes that are differentiallly expressed and 2) genes with differential exonic expression (alternative splicing).

2010-02-04 | GSE18838 | GEO

CIDR:NGRC PARKINSON'S DISEASE STUDY

Project description:CIDR:NGRC PARKINSON'S DISEASE STUDY

| PRJNA75909 | ENA

Whole-transcriptome high-throughput RNA sequencing of blood leukocytes from Parkinson's disease human patients pre- and post-deep brain stimulation

Project description:The given data set is the first deep sequencing transcriptome-wide data set of human Parkinson's disease (PD) patients RNA. The data set was produced from blood leukocytes of PD patients, from the same patients following deep brain stimulation (DBS), and from matched healthy control volunteers. Post-DBS samples were taken from the patients while being on electrical stimulation (ON-Stim), and following one hour off of electrical stimulation (OFF-Stim state). We have previously shown that gene expression changes, and in particular, alternative splicing changes, are observed in blood leukocytes and may contribute to PD and being subjected to regulation following DBS. Here, SOLiD RNA-Seq was applied to study the transcriptome of PD patients. Exon- and junction-level analyses revealed deep insight into both differential expression and alternative splicing regulation in PD blood leukocytes prior to and following DBS both on and off electrical stimulation. This transcriptome genome-wide data obtained through high-throughput sequencing of RNA produced from human Parkinson's disease (PD) patients blood leukocytes prior to treatment and following deep brain stimulation (DBS) neurosurgical treatment may yield insights into the molecular mechanisms that underlie the pathogenesis of PD and treatment efficacy. It may further enable the development of future diagnostics and therapeutics for PD. Blood leukocyte RNA was analyzed from 3 healthy control volunteers, and from 3 PD patients pre-DBS, ON-Stim, and OFF-Stim.

2014-07-16 | E-GEOD-42608 | biostudies-arrayexpress

Parkinson's disease vs. controls, whole blood

Project description:Parkinson’s disease (PD) progresses relentlessly and affects five million people worldwide. Laboratory tests for PD are critically needed for developing treatments designed to slow or prevent progression of the disease. We performed a transcriptome-wide scan in 105 individuals to interrogate the molecular processes perturbed in cellular blood of patients with early-stage PD. The molecular marker here identified is strongly associated with risk of PD in 66 samples of the training set (third tertile cross-validated odds ratio of 5.7 {P for trend 0.005}). It is further validated in 39 independent test samples (third tertile odds ratio of 5.1 {P for trend 0.04}). The genes differentially expressed in patients with PD, or Alzheimer’s or progressive supranuclear palsy offer unique insights into disease-linked processes detectable in peripheral blood. Combining gene expression scans in blood and linked clinical data will facilitate the rapid characterization of candidate biomarkers as demonstrated here with respect to PD. Keywords: disease state analysis

2006-12-30 | GSE6613 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data